MACOM

Phase A — Understand the business

Company Overview

MACOM designs and manufactures high-performance analog, RF, microwave, millimeter-wave, and photonic/optical semiconductor components — ICs, MMICs, multi-chip modules, diodes, amplifiers, switches, lasers and optical subsystems — that customers drop into larger systems: radar, basestations, optical-network line cards, satellites, test-and-measurement, medical. It is "the analog plumbing of high-frequency signal chains," not a digital-compute company. HQ Lowell, Massachusetts; >70 years of heritage (traces to Microwave Associates).

Three end markets (one reportable segment, but managed and disclosed as three):

• Industrial & Defense (I&D) — FY25 $419.8M, 43.4% of revenue, +19.4% YoY. Military/commercial radar, RF jammers, electronic countermeasures, space, plus multi-market catalog parts.
• Data Center — FY25 $292.8M, 30.3%, +48.0% YoY. Analog ICs + coherent/photonic components for 100G→1.6T→3.2T intra-data-center and DCI links. The growth engine.
• Telecom — FY25 $254.6M, 26.3%, +41.4% YoY. 5G/6G carrier infra, SATCOM, PON/FTTx, metro/long-haul.

Business model. ~6,000 end customers; thousands of catalog + custom parts. Sold via direct sales, independent reps, and distributors. No long-term volume contracts — almost entirely purchase-order and "turns" business (ship from inventory shortly after order), which makes backlog a weak predictor and quarters lumpy. Some products have 5–20-year life cycles (long-tail catalog annuities), others <5 years.

Customer concentration: no single direct customer ≥10%, but two resellers/distributors each exceeded 10% in FY25 — one at 12.4%, a second at 11.2% (these are the channel partners, e.g. the Richardson RFPD / Arrow-type distributors, not end demand). Distributors were 32.3% of revenue (up from 29.3% / 24.0%). Top-10 customers = 56.7%; top-25 direct = 45.6%. International = 56.3% of revenue; China 28.4%, rest-of-APAC 11.5% — meaningful geopolitical exposure.

Supply Chain

Upstream → MACOM → end customer, named where disclosed:

• Raw inputs: high-purity gallium, aluminum, arsenic, nitride, carbon, silicon; purchased wafers, packages, metals, PCBs from "hundreds of suppliers worldwide," purchase-order basis. Single-source risk is explicit: "wafers procured from merchant foundries for a particular process technology are generally sourced through a single foundry on which we rely for all of our wafers in that process." That is the key chokepoint.
• Fabrication (the differentiator): a fab-lite hybrid — internal compound-semi fabs at Lowell MA, RTP North Carolina, Ann Arbor MI, and Limeil-Brévannes France (GaAs, GaN, InP), supplemented by external foundries. The Lowell fab holds U.S. DoD "Trusted Foundry" accreditation — a structural moat for I&D (a domestic, secure source is often a requirement to win defense sockets). The RTP NC fab was assumed from Wolfspeed on 2025-07-25 as part of the RF-business acquisition, adding GaN-on-SiC capacity.
• Assembly/test: internal (Lowell, Nashua NH, Ann Arbor, Hamilton NJ, Morgan Hill CA, Limeil-Brévannes, Hsinchu Taiwan) + outsourced — "the majority of our contract assembly, packaging and test vendors are located in Asia."
• Downstream: OEMs, contract manufacturers, resellers, distributors → into hyperscaler data-center optics, defense primes, telecom-equipment OEMs.

Chokepoints: (1) single-foundry-per-process external wafer dependency; (2) Asian back-end concentration; (3) China both a 28% revenue market and a sanction/export-control flashpoint (BIS rules of Oct-2022/2023). Mitigants: multi-sourcing where feasible, U.S.-based front-end fabs, in-house Trusted Foundry.

Competitive Advantages (moats)

1. Trusted Foundry + U.S. compound-semi fabs — domestic GaAs/GaN/InP fabrication with DoD accreditation is genuinely scarce; it locks in defense design wins and is hard/slow to replicate. Real, durable moat for the I&D leg.
2. Process-technology breadth + design-win switching costs — MACOM can pick internal or external process per product, optimizing performance; once a part is designed into a customer's radar or optical line card, qualification cycles run a year-plus and switching is costly. Design-win lock-in is the classic analog moat.
3. Catalog longevity — thousands of long-life parts (some revenue-generating 20+ years) create an annuity base that smooths cyclicality.
4. IP — 729 U.S. + 497 foreign issued patents; 166 U.S. + 269 foreign pending (as of 2025-10-03), though management explicitly says future success rests "more [on] the innovation, technical expertise and management abilities of our engineers… than by patent ownership".

Bargaining power. Mixed. Over customers: weak on the giants (no >10% direct customer, but PO-only relationships mean customers can cancel/defer with little penalty) yet strong where it holds a Trusted-Foundry-only or sole-qualified-source position. Over suppliers: limited (single-foundry-per-process dependence). The honest read: the moat is technology + accreditation + design-win lock-in, not scale (rivals ADI/Broadcom/Marvell are far larger and explicitly "have greater financial resources and scale than us").

Segments

End-market revenue, FY (in $000s) and latest quarter:

MACOM reports a single operating segment, so segment EBITDA/EBIT by market is not disclosed — n/a at the segment-profit level. Trend read:

• Data Center is accelerating and re-mixing the company — 27.1% of revenue in FY24 → 30.3% FY25 → 34.0% in Q2-FY26, on AI-driven optical/coherent demand (100G→1.6T, now citing 3.2T). This is the lens that re-rated the stock.
• I&D steady high-teens/low-20s growth on defense programs + acquired content — the ballast.
• Telecom decelerated hard in the latest quarter (+7.6% Q2 vs +41.4% FY25) — worth watching; the FY25 number was flattered by 5G/SATCOM + acquired revenue and the 53rd week.

Phase B — Measure performance

Earnings Result (latest print: fiscal Q2 FY2026, ended 2026-04-03)

The cleanest way to read MACOM right now: operations are firing; GAAP is noisy from FY25's debt refinancing.

Income statement:

• Revenue $288.96M, +22.5% YoY (vs $235.9M), +6.4% sequentially.
• Gross profit $164.4M, GM 56.9% (record; up from 55.2% YoY). Adjusted GM 58.5%.
• Income from operations 17.6% of revenue (vs 14.8% YoY) — clear operating leverage.
• GAAP net income $46.3M, diluted EPS $0.60 (vs $0.42). Adjusted EPS $1.09, beat $1.07 consensus. The GAAP-to-adjusted gap ≈ SBC + intangible amortization (SBC alone ran $79.4M in FY25).
• H1 FY26 revenue $560.6M (+23.5%); H1 net income $95.1M vs a prior-year $(135.9)M loss — the swing is entirely the Q1-FY25 $193.1M convert-extinguishment charge rolling off.

Guidance (the real catalyst). For fiscal Q3 FY26: revenue $331–339M (mid $335M) and adjusted EPS $1.31–1.37 (mid $1.34) — both well above the ~$306M / ~$1.17 consensus going in. That implies ~+16% sequential revenue and a steep adjusted-EPS ramp.

Balance-sheet flags:

• Cash $98.5M + short-term investments $566.3M = ~$664.8M liquid.
• 2026 converts ($161.2M) repaid in cash in H1-FY26 → only the 0.00%-coupon 2029 converts ($344.3M) remain. Net cash ≈ +$320M (vs converts), still positive even after ~$67M of finance-lease + financing obligations.
• Inventory $252.2M — high, ~1.85× quarterly COGS, and the auditor's critical audit matter (excess/obsolescence judgment). AR $159.6M. Both grew with revenue but inventory bears watching in a PO/turns model.
• H1 OCF $121.6M; capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. $26.1M → H1 FCF ≈ $95M.

Market reaction & what was priced in. The Q3 guide drove the stock sharply higher; Barclays raised its target $400→$450 (2026-05-22) and Needham $250→$400 (2026-05-08). The tape says the market now prices MACOM as an AI-optical compounder, not a cyclical RF name. Unusual vs its own history: 56.9% GM is the highest in the dataset; the prior-year H1 GAAP loss is a refinancing artifact, not operational.

Earnings Calls (sentiment trend)

No transcripts on disk (transcripts=0); this lens is /inference from releases and is the dossier's softest. From the FY25 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. and Q2-FY26 release language, management's consistent focus: Data Center optical (100G→1.6T→3.2T), defense program ramps, design wins, and gross-margin expansion via the RTP fab and mix. The objective signal of rising confidence is behavioral: guiding Q3 ~16% above consensus and repaying the 2026 converts in cash rather than rolling them. Tone has shifted from "cyclical-recovery/integration" (FY24, RF-business + OMMIC + ENGIN-IC integration) to "secular AI/data-center demand" (FY25→FY26). To verify against the actual Q1/Q2-FY26 call transcripts — book-to-billBook-to-billNew orders divided by orders filled. Above 1 means the backlog is growing; below 1 means the company is working through it faster than it is replacing it., lead times, China commentary, and whether the Telecom deceleration is timing or trend.

Comps

Peer set: AI-optical/connectivity names MACOM competes with on the growth narrative, plus the RF-analog peers it competes with operationally. Multiples are, dated; ROE 5-yr averages and several EVEnterprise valueWhat it would cost to buy the whole company: its market value plus its debt, minus the cash you would get with it. Often very different from market cap. multiples are not sourced rather than fabricated.

Read. MACOM sits in a valuation no-man's-land that is actually flattering: at ~54× forward it is far cheaper than the NVIDIA-anchored optical pure-plays (Coherent/Lumentum at 150×+ trailing, each with a ~$2B NVDA strategic stake ) and modestly richer than Credo (~43× forward), yet a 3–4× premium to the RF-analog peers (Qorvo ~15×, Skyworks ~13×) that lack the AI-optical growth. The market is paying MACOM for the data-center optical story while it still carries a defense + telecom base the optical pure-plays don't have. The bull says that diversification deserves a premium to Credo; the bear says 54× already assumes the optical ramp compounds for years.

Stock-Price Catalysts (what moves MTSI)

Pattern over the last ~5 years and recently:

• Earnings + guidance are the dominant >5% movers — the Q3-FY26 guide (revenue ~9% above Street, adj-EPS ~15% above) is the textbook example; analyst target jumps ($250→$400, $400→$450) clustered on it.
• AI/data-center optical sentiment — MTSI now trades with the optical-interconnect complex (Coherent, Lumentum, Credo, Marvell). NVIDIA photonics headlines and hyperscaler capex prints move the whole group; MACOM rides that beta.
• Defense-budget / program news — the I&D ballast reacts to U.S. defense appropriations and program ramps.
• M&A — MACOM is a serial acquirer (Wolfspeed RF business, OMMIC/MESC, ENGIN-IC, Linearizer); deal announcements and the new April-2026 UK "Investee" stake (£30M equity + £15M convertible notes) are catalysts.
• China/export-control — BIS actions and China-demand swings are downside catalysts given 28% China revenue.
• The historical low-base anchor: non-affiliate market value was ~$5.7B as of April 2025; at ~$29.9B in June 2026 the stock has roughly 5×'d in ~14 months — the re-rate itself is the story, and it raises the bar.

Phase C — Judge people & books

Management

• CEO Stephen (Steve) Daly — appointed CEO May 2019, director since March 2015, Chairman since Nov 2023 (combined Chair/CEO — a mild governance flag). Track record is the strongest single qualitative positive: before MACOM he was President/CEO of Hittite Microwave (2004–2013) — a high-margin RF specialist acquired by Analog Devices for ~$2.45B in 2014, widely regarded as one of the best-run RF franchises of its era. He has run the same playbook at MACOM: portfolio focus, margin discipline, bolt-on M&A. Under him, cumulative TSR reached $329.94 on a $100 FY-base by FY2024 vs $234.89 for the PHLX Semiconductor Index — outperforming the SOX.
• Skin in the game: direct ownership only 0.041% ($11M) — modest for a founder-operator archetype; he is a professional manager, not a large owner. Flag: an insider sale of 100,000 shares has been reported — routine for a comp-heavy exec but worth tracking against the run-up.
• Capital allocation: reinvest-and-acquire, not return-of-capital — no dividend, no buyback program (the only "repurchases" are tax-withholding on vested RSUs; the publicly-announced-program column is nil). The signature 2025 move — exchanging/refinancing the 2026 converts into 0.00% 2029 converts + equity, then repaying the 2026 stub in cash — cost a $193.1M GAAP extinguishment charge but left the company with effectively interest-free leverage and a net-cash sheet. Defensible, even shrewd, financing.
• Comp: ~$10.1M total, ~92% variable/equity; say-on-pay 97.5% approval — shareholders are not agitated.
• Archetype: disciplined professional operator with a proven RF-franchise exit. Implication: execution risk is low; the risk is price paid, not management quality.

Forensic Red Flags

Income statement / balance sheet / cash flow scan:

• GAAP–operations divergence (benign): FY25 GAAP net loss $(54.2)M was driven entirely by the $193.1M non-cash debt-extinguishment loss; operating income was strong ($129.7M, +76% YoY) and OCF was $235.4M. Not an accounting red flag — but anyone screening on GAAP net income/P/E (trailing P/E ~170×) is being misled by a financing artifact.
• SBC is large and growing: $79.4M in FY25 (8.2% of revenue), up from $45.6M/$38.1M; it flatters non-GAAP/adjusted EPS (the $1.09 adj vs $0.60 GAAP gap). Real and dilutive — watch share count creep (basic shares 70.8M→74.0M over three years; ~74.9M at Nov-2025).
• Inventory is the auditor's critical audit matter — $252.2M (Apr-2026), excess/obsolescence reserve is a key judgment in a cyclical PO/turns model. Inventory + AR both growing; AR up to $159.6M. In a turns business, a demand air-pocket would expose this fast. The one balance-sheet line to monitor.
• Goodwill $335.6M + intangibles $67.4M from the acquisition spree — impairment risk if the acquired RF/defense content underperforms; none taken to date.
• Deferred tax asset $202.0M and a partial valuation allowance (a $10.1M allowance on foreign NOLs was added in FY25) — modest judgment area; effective tax rate is volatile (FY25 distorted to (86.8)% by the non-deductible extinguishment loss; FY26 guided ~17.3%).
• Customer/channel concentration: two distributors >10% each (12.4%, 11.2%) — revenue runs through a thin channel; a distributor de-stock would hit hard.

Regulatory findings:

• SEC Litigation Releases: none naming MACOM (2021-06-22 → 2026-06-22).
• SEC AAERs: none.
• 10-K Item 3 / 10-Q Legal Proceedings: the company states it "was not involved in any material pending legal proceedings" during the period; the 10-K describes only ordinary-course IP-indemnity exposure.
• Non-SEC enforcement (FTC/DOJ/FDA/BIS): no material public hits surfaced; the relevant regulatory exposure is prospective (BIS export controls on China, ITAR/EU dual-use for defense parts), not an existing action.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 / 10-Q Note 13 as of 2026-06-22. Auditor Deloitte & Touche since 2010; unqualified opinion incl. ICFR.

Phase D — Project & stress-test

Forward Projection (adjusted EPS, fiscal years ending ~early Oct)

Built bottom-up from the latest actuals + the company's own Q3-FY26 guide, into base/bull/bear. All outputs; inputs labeled. MACOM's fiscal years: FY26 ends ~2026-10-02, FY27 ~2027-10-01, FY28 ~2027-09(FY28 end).

Anchors: H1-FY26 adjusted EPS ≈ $1.09 (Q2) + ~$1.0x (Q1); Q3-FY26 guide adj-EPS mid $1.34; analyst framing ~+13–14% revenue CAGR, ~+16% EPS growth through FY28. FY25 revenue $967.3M.

Valuation cross-check. At ~$391, base FY26 ~$4.90 ⇒ ~80× FY26 / ~65× FY27 adj EPS — richer than the ~54× "forward" figure the screens quote (the screen is likely blending a higher Street FY27 or a NTM number). Either way the multiple is full: MACOM is priced for the bull path to substantially hit. Forecast NOT logged to our model — --watchlist breadth rule (log a Brier forecast only on genuine committed conviction, done in our position log). The honest base case: a high-quality compounder whose fundamentals justify a premium but whose current price already embeds several years of the optical ramp.

Bull vs Bear

Bull case. Three secular legs rarely found together in one mid-cap: (1) AI data-center optics — the only leg the market is paying for, growing 36–48%, re-mixing the company toward higher-value coherent/photonic content at 100G→3.2T; (2) U.S. defense — Trusted-Foundry-protected, budget-tailwind, sticky; (3) telecom/5G/SATCOM — cyclical but real. Layer on 56.9% record gross margins and a fab-lite + net-cash balance sheet after the convert cleanup, a proven operator (Daly/Hittite), and interest-free 2029 leverage. If data-center optics compounds and telecom re-accelerates, FY28 adj EPS pushes toward $8–9 and the premium is earned. Contrarian view the market underrates: MACOM is the diversified, profitable, U.S.-fab way to own AI optical content — less single-customer-fragile than the NVDA-anchored pure-plays, yet it trades at a fraction of their multiple.

Bear case — what could permanently impair or de-rate:

1. Multiple compression. At ~54–80× forward, MACOM has re-rated ~5× in 14 months. A single soft guide, an optical-capex digestion quarter, or a rotation out of the AI-optical complex (Coherent/Lumentum at 150×+ are unstable) could halve the multiple with no change in the business.
2. China + export controls. 28% of revenue; BIS rules can cut access overnight and seed domestic Chinese competitors MACOM explicitly fears.
3. Telecom deceleration is already visible (+7.6% Q2 vs +41.4% FY25). If that's trend not timing, the "three secular legs" story loses one.
4. Inventory/turns fragility — $252M inventory in a no-backlog PO model; a demand air-pocket triggers write-downs and a margin reset (the auditor flagged exactly this).

Pre-mortem (18 months out, thesis broke). Most likely: AI data-center optical demand "digests" after a hyperscaler capex pause; MACOM misses a quarter or guides flat; the optical complex de-rates from 150×→80×, dragging MTSI from ~54× to ~30× forward — a 40%+ drawdown — even though revenue still grew ~15%. The business is fine; the price was the risk.

Devil's Advocate (short-seller)

Dismantling the bull case. What structurally breaks the money machine? Revenue concentration sits in the channel, not the logo — two distributors are >10% each and distributors are 32% of sales; a channel de-stock (which the company can't see, by its own admission of "limited visibility into customers' inventories") would crater a quarter. The moat is narrower than bulls think on the growth leg: the Trusted-Foundry/defense moat is real, but in data-center optics MACOM competes head-on with Broadcom, Marvell, Credo, Coherent and Lumentum — far larger, better-capitalized, several NVDA-anchored. MACOM is a content supplier into optical modules, not the architect of the link; it can be designed around. The most dangerous competitor bulls underestimate: Broadcom/Marvell vertical integration in optical DSP + the silicon-photonics push (NVIDIA-funded at Coherent/Lumentum) could commoditize the discrete analog/photonic content MACOM sells. Worst capital-allocation/accounting tells: none egregious, but a serial-acquirer with $336M goodwill, $79M-and-rising SBC flattering adjusted EPS, a combined Chair/CEO, and a CEO trimming 100k shares into the run is a profile that demands scrutiny. What must hold for ~$391: ~15%+ revenue CAGR and a sustained 50×+ multiple for years. If growth disappoints 20–30%: at ~30× a $4.4 bear FY26 EPS, fair value ≈ $130 — a ~65% drawdown from here. Single scenario that permanently impairs: a China export-control regime that removes 28% of revenue and hands the share to subsidized domestic competitors — plausible-but-not-base.

Management Questions (ordered by information value)

1. Of the Data-Center +36% YoY, how much is new design-win content (1.6T/3.2T sockets) vs. share-of-wallet at existing customers vs. price — and what is the design-win backlog you can't yet see in revenue?
2. Telecom decelerated to +7.6% in Q2 from +41% in FY25 — timing/53rd-week artifact, or a genuine demand roll-over? What's the FY26 exit trajectory?
3. What is current book-to-bill and lead-time trend by end market, and how much of the Q3 guide is backlog vs. expected turns?
4. With 28% of revenue in China, what is your concrete contingency if BIS tightens controls on your RF/optical parts — and how much revenue is already export-license-gated?
5. The two >10% distributors: how much end-demand visibility do you actually have through them, and what's your channel-inventory read right now?
6. Adjusted EPS is ~$0.49 above GAAP largely on SBC ($79M FY25). What's the multi-year SBC-as-%-of-revenue and share-count dilution path?
7. Capital allocation: with net cash and 0% 2029 converts, why no buyback to offset SBC dilution — and what's the M&A vs. return-of-capital priority?
8. Walk through the new UK "Investee" investment (£30M + £15M notes) — strategic rationale, what it gets you, and is this a template for more minority stakes?
9. Gross margin hit a record 56.9% (58.5% adj). How much is mix (data-center/defense) vs. RTP-fab utilization, and where does structural GM top out?
10. Inventory is $252M with no backlog and it's your auditor's critical audit matter — how do you size obsolescence risk in a turns model heading into a possible optical digestion?
11. RTP (ex-Wolfspeed) GaN-on-SiC: utilization, yield maturity, and incremental margin as it scales?
12. CHIPS Act: status of the ≤$70M award and the 25%→35% ITC — quantify the capex/cash benefit and timing.
13. Where are you on silicon photonics vs. discrete optics — is co-packaged/silicon-photonics a threat or an opportunity to your analog content?
14. Defense: which programs drive I&D, what's the multi-year visibility, and how exposed are you to U.S. budget continuing-resolution risk?
15. Five-year frame: which of the three legs is the largest by FY30, and what's the ceiling on data-center as a % of revenue before customer-concentration risk bites?